Hybrid Adeno-Retroviral Vector for the Transformation of Cells (E-312-2000)
Description of Invention:
The invention described and claimed in these patent applications provides for novel hybrid vectors which may be used for cell transformation either in vivo, in vitro, or ex vivo. The hybrid vectors, which are capable of integrating into the chromosome of the host cell and are capable of transducing dividing and non-dividing cells, have an adenoviral serotype 5 backbone and two retroviral (Moloney murine leukemia virus) elements upstream and downstream of the transgene. These elements include part of the envelope sequence, the long terminal repeat (LTR) and the packaging signal sequence (upstream), and part of the envelope sequence and LTR (downstream). Due to their hybrid nature, these vectors provide a means of efficient, reliable, long-term gene expression. Furthermore, unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest and retroviral functional proteins are not required. The vectors are packaged and delivered via an adenoviral particle and administered directly to the target cell.
Inventors:
Changyu Zheng (NIDCR) Brian O'Connell (NIDCR) Bruce J. Baum (NIDCR)
Patent Status:
DHHS Reference No. E-312-2000/0-US-01 filed 30 Jan 2001 (U.S. Provisional Application No. 60/265,198)
DHHS Reference No. E-312-2000/0-PCT-02 filed 25 Jan 2002, which published as WO 02/061104 on 30 Jul 2002 (PCT Application No. PCT/US02/02279)
DHHS Reference No. E-312-2000/0-US-03 filed 29 Jul 2003 (U.S. Patent Application No. 10/470,784)
Relevant Publication:
Zheng et al., “Inclusion of Moloney murine leukemia virus elements upstream of the transgene cassette in an E1-deleted adenovirus leads to an unusual genomic integration in epithelial cells,” Virology 2003 313:460-72, 2003.
Zheng et al., “Integration efficiency of a hybrid adenoretroviral vector,” Biochem Biophys Res Commun. 300:115-20, 2003.
Zheng & Baum, “Long-term expression after infection by the hybrid vector AdLTR-luc is from integrated transgene,” Biochem Biophys Res Commun. 291:34-40, 2002.
Portfolios: Gene Based Therapies
Gene Based Therapies -Therapeutics-Gene Therapy-Vectors Gene Based Therapies -Therapeutics-Gene Therapy-Delivery Systems Gene Based Therapies -Therapeutics
For Additional Information Please Contact: Jasbir (Jesse) S. Kindra J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5559
Email: kindraj@mail.nih.gov
Fax: (301) 402-0220
